共 50 条
- [1] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 43, 10.1200/JCO-24-02469, 2024)JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01) : 113 - 113Rastogi, Priya
- [2] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09) : 987 - 993Rastogi, PriyaO'Shaughnessy, JoyceMartin, MiguelBoyle, FrancesCortes, JavierRugo, Hope S.Goetz, Matthew P.Hamilton, Erika P.Huang, Chiun-ShengSenkus, ElzbietaTryakin, AlexeyCicin, IrfanTesta, LauraNeven, PatrickHuober, JensShao, ZhiminWei, RanAndre, ValerieMunoz, MariaSan Antonio, BelenShahir, AshwinHarbeck, NadiaJohnston, Stephen
- [3] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomesANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256Harbeck, N.Rastogi, P.O'Shaughnessy, J.Boyle, F.Cortes, J.Rugo, H. S.Goetz, M. P.Hamilton, E. P.Huang, C.Senkus-Konefka, E.Tryakin, A.Neven, P.Huober, J.Wei, R. J.Andre, V.Munoz, M.Antonio, B. SanShahir, A.Jimenez, M. MartinJohnston, S. R. D.
- [4] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy OutcomesBREAST, 2025, 80Andre, V.Harbeck, N.Rastogi, P.O'Shaughnessy, J.Boyle, F.Cortes, J.Rugo, H. S.Goetz, M. P.Hamilton, E.Huang, C. -s.Senkus, E.Tryakin, A.Neven, P.Huober, J.Wei, R.Munoz, M.Antonio, B. S.Shahir, A.Martin, M.Johnston, S.
- [5] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomesONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 227 - 228Reinisch, MatteaHarbeck, NadiaRastogi, PriyaO'shaughnessy, JoyceBoyle, FrancesCortes, JavierRugo, Hope S.Hamilton, ErikaGoetz, Matthew P.Huang, Chiun-ShengSenkus, ElzbietaTrakin, AlexeyNeven, PatrickHuober, JensRan, WeiAndre, ValerieMunoz-Fernandez, MariaAntonio, Belen SanShahir, AshwinMartin, MiguelJohnston, Stephen
- [6] Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast CancerBREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 517 - 527O'Keefe, KaitlynDesai, Neelam, VTan, Antoinette R.
- [7] Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3699 - +Bachelot, ThomasCottu, PaulChabaud, SylvieDalenc, FlorenceAllouache, DjelilaDelaloge, SuzetteJacquin, Jean-PhilippeGrenier, JulienBouvet, Laurence VenatJegannathen, ApurnaCampone, MarioDel Piano, FrancescoDebled, MarcHardy-Bessard, Anne-ClaireGiacchetti, SylvieMouret-Reynier, Marie-AngeBarthelemy, PhilippeKaluzinski, LaureMailliez, AudreyLegouffe, EricSephton, MatthewBliss, JudithCanon, Jean-LucPenault-Llorca, FrederiqueLemonnier, JeromeCameron, DavidAndre, Fabrice
- [8] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2023, 24 (01): : 77 - 90Johnston, Stephen R. D.Toi, MasakazuO'Shaughnessy, JoyceRastogi, PriyaCampone, MarioNeven, PatrickHuang, Chiun-ShengHuober, JensJaliffe, Georgina GarnicaCicin, IrfanTolaney, Sara M.Goetz, Matthew P.Rugo, Hope S.Senkus, ElzbietaTesta, LauraDel Mastro, LuciaShimizu, ChikakoWei, RanShahir, AshwinMunoz, MariaSan Antonio, BelenAndre, ValerieHarbeck, NadiaMartin, Miguel
- [9] Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/ human epidermal growth factor receptor 2-negative early breast cancerJOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (09): : 942 - 953Chang, Shao-HsuanSvensson, MikaelWang, Grace Hsin-MinWang, YehuaKang, Hye-RimPark, Haesuk
- [10] Final overall survival analysis of MONARCH 2: a Phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative Advanced Breast CancerONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 30 - 30Grischke, E. M.Llombart-Cussac, A.Toi, M.Neven, P.Sohn, J.Inoue, K.Pivot, X.Okera, M.Masuda, N.Kaufman, P. A.Koh, H.Conte, P.Andre, VBian, F.Shahir, A.van Hal, G.Sledge Jr, G. W.